Home › Research › Treatments
DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study
Ilise Lombardo, Geetha Ramaswamy, Stephen C. Piscitelli, Lawrence T. Friedhoff. Alzheimer s & Dementia, 2015-07-01
Topic: Drug trials: efficacy and safety
Plain-language summary
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. We present the results of an analysis of observed data from a randomized, double-blind, placebo-controlled Phase 2b study. In this study, 684 subjects with mild to moderate Alzheimer's disease were randomized to receive 35 mg RVT-101, 15 mg RVT-101, or placebo as an adjunct to stable donepezil treatment. The study included a 24-week double-blind randomized phase and an optional, additional 24-week blinded extension. An analysis of covariance (ANCOVA) method was used to evaluate multiple endpoints on cognition and function based on observed data, including the ADAS-cog, CDR-SB, and ADCS-ADL at weeks 12, 24, 36, and 48. The proportion of subjects completing the study ranged from 86-89% from week 0 to week 24 and from 87-89% from week 24 to week 48. On ADAS-cog and ADCS-ADL respectively, subjects who received 35 mg RVT-101 achieved a 1.29 (p = 0.008) and 1.72 (p = 0.016) point benefit at week 12; a 1.63 (p = 0.007) and 2.11 (p = 0.016) point benefit at week 24; and a 1.82 (p = 0.018) and 2.34 (p = 0.048) point benefit at week 48, all compared to donepezil alone. Subjects who received 35 mg RVT-101 achieved a statistically significant benefit on CDR-SB compared to subjects who received donepezil alone only at 12 weeks after initiation of treatment. Mean ADAS-cog, ADCS-ADL and CDR-SB values for the 15-mg group were generally numerically superior to placebo but the differences were not statistically significant. In this analysis of subjects completing a Phase 2b study in subjects with mild-to-moderate Alzheimer's disease, the 35 mg dose of RVT-101 was shown to be effective in improving cognition and function as an adjunct to stable donepezil at multiple time points. Given the low drop-out rate, this analysis provides an accurate representation of the study. The 35 mg dose of RVT-101 will be advanced into a Phase 3 study in the second half of 2015.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. T. (2015). DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.08.154
Vancouver
Lombardo I, Ramaswamy G, Piscitelli SC, Friedhoff LT. DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.08.154.
BibTeX
@article{lombardo2015-d54d3985,
author = {Lombardo, Ilise and Ramaswamy, Geetha and Piscitelli, Stephen C. and Friedhoff, Lawrence T.},
title = {{DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study}},
journal = {Alzheimer s \& Dementia},
year = {2015},
doi = {10.1016/j.jalz.2015.08.154},
url = {https://doi.org/10.1016/j.jalz.2015.08.154}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We present the results of an analysis of observed data from a randomized, double-blind, placebo-controlled Phase 2b study.
- On ADAS-cog and ADCS-ADL respectively, subjects who received 35 mg RVT-101 achieved a 1.29 (p = 0.008) and 1.72 (p = 0.016) point benefit at week 12; a 1.63 (p = 0.007) and 2.11 (p = 0.016) point benefit at week 24; and a 1.82 (p = 0.018) and 2.34 (p = 0.048) point benefit at week 48, all compared to donepezil alone.
- Subjects who received 35 mg RVT-101 achieved a statistically significant benefit on CDR-SB compared to subjects who received donepezil alone only at 12 weeks after initiation of treatment.
- Mean ADAS-cog, ADCS-ADL and CDR-SB values for the 15-mg group were generally numerically superior to placebo but the differences were not statistically significant.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants684
- Evidence strengthHigh
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 684 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.